🔥 Trending Gene Therapy Trial in China Linked to Young Girl's Death

An experimental gene therapy trial in China has come under scrutiny following the death of a 6-year-old girl named Mei, who was undergoing treatment for a rare neurodevelopmental syndrome ²⁸. The incident, which occurred in 2025, sparked an investigation by Science and Retraction Watch, raising significant questions about the ethics and safety of gene therapy research, particularly in China ²³⁵.

Details of the Incident

Mei received an experimental gene-editing therapy at Xinhua Hospital in China on March 24, 2025 ⁵. The therapy involved injecting gene therapy-laden viruses into her spinal fluid after she was given a steroid to suppress potential immune reactions ⁵. Tragically, Mei died after receiving this treatment ².

A critical aspect of this case is that the family of the deceased girl paid over $800,000 to fund the development of this specific therapy ¹. This financial arrangement was not disclosed in the published research paper about the trial, nor was Mei's death ¹⁷. The family has since requested the withdrawal of the paper ¹.

Ethical and Regulatory Concerns

Lack of Transparency

The primary concern highlighted by the investigation is the lack of transparency surrounding Mei's death. Neither the death itself nor the family's financial contribution to the therapy's development was publicly disclosed in the research findings ¹⁷. Experts have indicated that these omissions may warrant a retraction of the published paper ¹.

Regulatory Oversight

China's regulatory system for gene therapy trials has been a focal point of the controversy. At the time of Mei's treatment, the trial did not require approval from a national regulatory body equivalent to the U.S. Food and Drug Administration (FDA) before proceeding ⁵. This allowed the trial to move forward without a high level of external scrutiny.

An ethics panel at Xinhua Hospital initially approved the gene-editing trial ³. However, this panel reportedly did not review primate data that suggested potential safety concerns ³. A subsequent hospital panel later concluded that the experimental treatment was "definitely related" to Mei's death ³.

Individualized Treatment and Children

The case also brings to light the complexities and ethical challenges associated with individualized gene therapies, especially when administered to children ⁸. Such treatments, often tailored for rare diseases, carry inherent risks that require stringent ethical review and oversight.

Recent Regulatory Changes in China

In response to growing concerns and incidents like Mei's death, China has revamped its regulations concerning cell and gene therapy research. In June 2026, new rules were introduced to restrict cutting-edge trials to specific hospitals and to ban institutions from charging patients fees related to such experimental treatments ⁴. These changes, which came into effect in May 2026, aim to incentivize hospitals to conduct early cell and gene therapies while presumably enhancing patient safety and ethical standards ⁶.

A Chinese university is currently investigating the reports surrounding the girl's death ⁷. The outcome of this investigation and the impact of the new regulations will be crucial for the future of gene therapy research in China and globally.